SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

253 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-21

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Among the etiologies of thrombosis, myeloproliferative neoplasia (MPN) is quite rare but should be investigated in case of thrombosis of atypical localization (digestive or cerebral) or in the context of recurrent idiopathic thrombosis in a young subject. Thrombosis could reveal an underlying MPN through the identification of a JAK2 V617F mutation. Rarely, MPN with thrombotic complications present with normal complete blood count(CBC). In case of a MPN with a thrombotic event but without CBC abnormality, anti-thrombotic treatment is recommended. But there is no recommendation for the indication of cytoreductive therapy and the clinician's decision is often empirical.

One of the major complications of for essential thrombocythemia (ET) or polycythemia vera (PV) is thrombosis and an age over 60 is a major risk factor. The treatment of thrombosis associated with TE or PV is based on recommendations the main therapeutic objective of which is to reduce the thrombotic risk. The combination of a cytoreducing agent and antithrombotic treatment is thus proposed in high-risk patients. The efficacy of this management is monitored by assessing CBC with the objective of normalization at \<400 G/L of platelets for ET patients and \<45% hematocrit in case of PV.

The absence of abnormal CBC makes it difficult to justify cytoreduction. The benefit of such a therapy in this context has not been clinically demonstrated. If a cytoreductive therapy is initiated, no biological parameters are available to assess the response to treatment.

The objective of this observational study is to evaluate the incidence of recurrence of thrombosis in patients whose thrombotic event revealed an underlying MPN with normal CBC. A comparison of groups treated or not with cytoreductive agents will be performed. Longitudinal monitoring of the patients will provide a better understanding of the nature and kinetics of hematological changes in these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)

NCT05419648

Myeloproliferative Neoplasm

COMPLETED

Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)

NCT05839717

Myeloproliferative Neoplasm

RECRUITING

Risk Factors and Predictors of Thrombosis in Myeloprolferative Neoplasms

NCT03599700

Thrombosis

UNKNOWN

A Trial of Hetrombopag in Healthy Subjects

NCT05088174

Sever Aplastic Anaemia

COMPLETED PHASE1

Bleeding In Thrombocytopenia Explained

NCT03505086

Hematologic Neoplasms Bleeding Hemorrhage +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is observational and multicentric.In a first part, patients will be retrospectively included. Baseline clinical and biological data obtainedat the time of MPN diagnosis of MPN with normal CBC following venous or arterial thrombosis will be recorded and follow-up data will be collected in an e-CRF. In a second part, patients will be included prospectively and diagnostic and follow-up data will be collected. Whether or not to initiate treatment with a cytoreduction treatment is left to the discretion of the clinician.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombotic Patients Diagnosis of Myeloproliferative Neoplasia Impact of Treatment With Cytoreducing Agent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult ≥18 years old
* Diagnosis of a deep arterial or venous thrombotic event verified by imaging (Doppler or CT scan)
* Diagnosis of MPN with normal CBC according to WHO 2017 criteria characterized by the detection of a molecular abnormality JAK2V617F mutation (regardless of allelic load), CALR or MPL and/or a bone marrow biopsy with abnormalities in favor of MPN.
* Normal blood cell count not suggestive of polycythemia vera (hematocrit\<48% and hemoglobin\<16g/dL for women; hematocrit\<49% and hemoglobin\<16.5g/dL for men), essential thrombocythemia (platelets\<450 G/L) nor myelofibrosis (white blood cell count\<11 G/L, no anemia or erythromyelemia associated with splenomegaly) at the time of the thrombotic event.

Exclusion Criteria

* Minors (\<18 years of age)
* Microcirculation disorders (erythromelalgia, headaches, paresthesia, ischemia of the extremities)
* Superficial or deep arterial or venous thrombosis NOT verified by imaging
* Diagnosis or history of TE, PV or myelofibrosis at time of first thrombotic event
* Diagnosis of mixed myelodysplastic/myeloproliferative syndrome
* Diagnosis of unclassifiable MPN with excess blasts at the onset or signs of myelodysplasia as defined by the WHO 2017 classification

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No